pharmaceutical-investing Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges
pharmaceutical-investing Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
pharmaceutical-investing Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
pharmaceutical-investing Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results
pharmaceutical-investing Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding
